User profiles for Jeffrey N. Bryan

Jeffrey Bryan

Professor of Oncology, University of Missouri
Verified email at missouri.edu
Cited by 2614

A population study of neutering status as a risk factor for canine prostate cancer

JN Bryan, MR Keeler, CJ Henry, ME Bryan… - The …, 2007 - Wiley Online Library
BACKGROUND Prostate cancer has been reported to occur more commonly in neutered
than intact male dogs in several case series. This study was undertaken to evaluate risk of …

Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms

JA Villamil, CJ Henry, JN Bryan… - Journal of the …, 2011 - Am Vet Med Assoc
Objective —To identify the most common cutaneous neoplasms in dogs and evaluate breed
and age distributions for selected neoplasms. Design —Retrospective epidemiological study…

[HTML][HTML] Hormonal and sex impact on the epidemiology of canine lymphoma

JA Villamil, CJ Henry, AW Hahn, JN Bryan… - Journal of cancer …, 2009 - hindawi.com
The Surveillance Epidemiology and End Results data demonstrate that the risk of non-Hodgkin
lymphoma is lower for women, but that the incidence increases after fifty years of age, at …

Primary renal neoplasia of dogs

JN Bryan, CJ Henry, SE Turnquist… - Journal of Veterinary …, 2006 - Wiley Online Library
… coma (n 5 12), renal sarcoma (n 5 7), leiomyosarcoma (n 5 4), malignant fibrous histiocytoma
(… by ultrasound in the contralateral kidney (n 5 1), spleen (n 5 1), and liver (n 5 2) in 4 dogs. …

Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer

…, J Kelsey, CS Cutler, KA Selting, JN Bryan… - International journal …, 2014 - Taylor & Francis
Introduction Gum arabic-coated radioactive gold nanoparticles (GA- 198 AuNPs) offer several
advantages over traditional brachytherapy in the treatment of prostate cancer, including …

[HTML][HTML] Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation

…, RA Beckman, LL Borkon, JN Bryan… - Frontiers in Digital …, 2022 - frontiersin.org
WWe are rapidly approaching a future in which cancer patient digital twins will reach their
potential to predict cancer prevention, diagnosis, and treatment in individual patients. This will …

Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a prospective, randomized trial of 324 …

…, SE Lana, K Weishaar, BK Flesner, JN Bryan… - Clinical Cancer …, 2021 - AACR
Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that participates
in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is …

A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent

…, T Ganguly, H He, T Liu, P Benny, JN Bryan… - The …, 2012 - Wiley Online Library
BACKGROUND Prostate‐specific membrane antigen (PSMA) remains an active target for
imaging and therapeutic applications for prostate cancer. METHODS In the present study, an …

Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma

…, TA Wahaus, JN Bryan, N Reyes - Journal of Veterinary …, 2020 - Wiley Online Library
Background Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent
chemotherapy failure and translational relevance for human health. Hypothesis/Objectives We …

NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma

…, E Krick, D Vail, M Childress, JN Bryan… - Clinical Cancer …, 2018 - AACR
Purpose: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved,
the camptothecins with irinotecan and topotecan widely used. Because of their limitations (…